AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
AbbVie (ABBV) has reduced its full-year earnings guidance, citing the expected dilution from its recent acquisition of Apogee. This adjustment was announced on Friday. The article notes that a premium subscription is required to read the full details of this announcement.
Why it matters
Attributed market update with source link for portfolio context.